Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares China Large-Cap ETF (FXI) vs Dr. Reddy's Laboratories Ltd Common Stock (RDY) Price & Performance

iShares China Large-Cap ETFTrade
Dr. Reddy's Laboratories Ltd Common StockTrade

Price performance (Past 24H)

Key statistics

iShares China Large-Cap ETF vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? iShares China Large-Cap ETF trades at $33.85 (market cap $3.90B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 2.7× iShares China Large-Cap ETF's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 151 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.

FXIRDY
Market Cap
$3.90B$10.61B
Volume
21,620,5203,738,869
52-Week High
$41.08$15.38
52-Week Low
$31.59$11.38
Typical Hold Time
151 Days0 Days
Sector
—Health
Enterprise Value
—$10.51B
Dividend Yield
—0.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares China Large-Cap ETF

FXI trades at $34.17 with minimal daily movement (+0.09%). The technical picture is bearish with moving averages signaling caution, though oscillators are neutral. Recent news highlights China's economic challenges including industrial overcapacity and weak domestic consumption, while corporate profits surged 26% in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54, offering potential value amid high political risk.

FXI presents a contrarian opportunity for investors seeking China exposure at discounted valuations, but faces substantial headwinds from U.S.-China tensions and domestic economic rebalancing. The ETF's heavy financial sector weighting and state-backed monetary support provide stability, though momentum remains weak. Key risks include escalating trade protectionism and China's export control uncertainties.

Dr. Reddy's Laboratories Ltd Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FXI
10% Buy90% Sell
Avg holding period · 151 Days
RDY
100% Buy0% Sell
Avg holding period · 0 Days

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI →

About Dr. Reddy's Laboratories Ltd Common Stock

Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.

Read more on RDY →